HJV

Across TCGA pan-cancer cohorts, HJV Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HJV data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HJV Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HJV expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, CESC, and UCEC are the cancer types where HJV Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.055	0.544	<.001	20	view →
CESC	OS	Median	All	0.277	0.798	.012	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.842	0.225	.034	4	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
COAD	DFS	Median	All	0.495	0.784	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HJV–LIHC (DFS)

Open the LIHC breakdown →